SLC6A3 and Parkinson disease: The validity of the α-SYN rAAV2/7 PD rat model has been demonstrated by extensive histopathological and biochemical analysis, motor behavior testing and in vivo microdialysis, including non-invasive longitudinal monitoring of neurodegeneration using PET imaging of the dopamine transporter (DAT) and magnetic resonance spectroscopy (MRS)19.